Navigation Links
Lux Biosciences' Investigational Therapy for Uveitis, LX211, is,Subject of Two Presentations at Key Ophthalmology Meeting, ARVO,2007

JERSEY CITY, N.J.--(BUSINESS WIRE)--May 4, 2007 - Lux Biosciences, Inc., a privately held biotechnology company specialized in the field of ophthalmic diseases, announced today that the company's next-generation calcineurin inhibitor, LX211, is the subject of two presentations at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting, being held May 6-10 in Fort Lauderdale, Florida.

The first, an oral presentation being given on May 5 during a satellite session of the American Uveitis Society by Quan Dong Nguyen, M.D. of the Wilmer Eye Institute, Johns Hopkins University and Hospitals, discusses the design of the ongoing LUMINATE (Lux Uveitis Multicenter Investigation of a New Approach to TrEatment) Phase 2/3 Clinical Trial Program. The three LUMINATE trials represent the first clinical development program aimed at supporting regulatory approval of a corticosteroid-sparing immunosuppressive agent in different types of sight-threatening, non-infectious uveitis.

The second, a poster presentation by Matthew A. Cunningham, senior medical student, senior author Robert Nussenblatt, MD, and collaborators from the National Eye Institute, Lux Biosciences, and Isotechnika, Inc., discusses preclinical data demonstrating the ability of subcutaneous injections of LX211 to prevent and reverse experimental autoimmune uveoretinitis (EAU) in rats. Cunningham commented, "We observed that in this animal model, LX211 could both prevent the onset of disease as well as reverse EAU at doses as low as 10 mg/kg. These preclinical results clearly support our view that LX211 may play an important future role in the treatment of uveitis."

The poster describes the induction of EAU in rats, which were then divided into three groups, designated preventative, therapeutic, and vehicle-control. Animals in the first two groups received daily subcutaneous injections of either cyclosporine A (CsA) at 40 mg/kg
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
3. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
4. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
5. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
11. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
Post Your Comments:
(Date:8/28/2015)... and LONDON , August 28, ... approach seamlessly connects people, ... improving outcomes and the cost ... PHG AEX: PHIA) today announced its presence at  ESC ... cardiology solutions, including Heart Model A.I. , EchoNavigator and IntelliSpace ...
(Date:8/27/2015)... , Aug. 27, 2015 Biosimilars ... (BPC) applauds the U.S. Food and Drug Administration ... distinguishable name in its draft guidance issued today. ... biological products proposes distinguishable names, calling for biological ... an FDA-designated suffix. This proposal reflects the agency,s ...
(Date:8/27/2015)... Women Grow , the fastest-growing professional networking organization for women ... Cannabis World Congress & Business Exposition (CWCBExpo) in ... sessions. CWCBExpo in LA will take place September 16-18, 2015 ... in Los Angeles, CA , and is ... marijuana industry. The Women Grow tracks at ...
Breaking Medicine Technology:Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 2Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 3Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 4Biologics Prescribers Collaborative (BPC) Statement on FDA Draft Guidance entitled "Nonproprietary Naming of Biological Products" 2Cannabis World Congress in Los Angeles Boasts Women Grow Sponsored Education 2Cannabis World Congress in Los Angeles Boasts Women Grow Sponsored Education 3Cannabis World Congress in Los Angeles Boasts Women Grow Sponsored Education 4
... April 28, 2011 Reportlinker.com announces that ... in its catalogue: ... and Drug Regulatory Overview: Cost-containment and regulatory ... http://www.reportlinker.com/p0487111/Pharmaceutical-Key-Trends-2011---Healthcare-System-and-Drug-Regulatory-Overview-Cost-containment-and-regulatory-pressures-intensify.html Introduction ...
... United Therapeutics Corporation (NASDAQ: UTHR ) today announced ... 2011. "I,m very pleased that we are cruising ... up almost 30% from a year ago," remarked Martine Rothblatt, ... now have a year,s experience with our product launches, we ...
Cached Medicine Technology:Reportlinker Adds Pharmaceutical Key Trends 2011 - Healthcare System and Drug Regulatory Overview: Cost-containment and regulatory pressures intensify 2Reportlinker Adds Pharmaceutical Key Trends 2011 - Healthcare System and Drug Regulatory Overview: Cost-containment and regulatory pressures intensify 3Reportlinker Adds Pharmaceutical Key Trends 2011 - Healthcare System and Drug Regulatory Overview: Cost-containment and regulatory pressures intensify 4Reportlinker Adds Pharmaceutical Key Trends 2011 - Healthcare System and Drug Regulatory Overview: Cost-containment and regulatory pressures intensify 5Reportlinker Adds Pharmaceutical Key Trends 2011 - Healthcare System and Drug Regulatory Overview: Cost-containment and regulatory pressures intensify 6United Therapeutics Corporation Reports First Quarter 2011 Financial Results 2United Therapeutics Corporation Reports First Quarter 2011 Financial Results 3United Therapeutics Corporation Reports First Quarter 2011 Financial Results 4United Therapeutics Corporation Reports First Quarter 2011 Financial Results 5United Therapeutics Corporation Reports First Quarter 2011 Financial Results 6United Therapeutics Corporation Reports First Quarter 2011 Financial Results 7
(Date:8/29/2015)... ... , ... Dr. Tim Novelli, DC., Founder and President of the Patriot Project, ... the chiropractic field in the military. All too often VA hospitals treat patients with ... available to the VA program over a decade ago, the reality is that only ...
(Date:8/29/2015)... (PRWEB) , ... August 29, 2015 , ... ProDrop Particles ... . Each preset contains 15 seconds of unique footage that users can shrink and ... fall, zoom, attract and more. Users can customize color, brightness, scale, speed, range, and ...
(Date:8/29/2015)... ... August 29, 2015 , ... The popular television program VOICES IN AMERICA, hosted ... it will be devoting an entire short segment to the subject of diabetes. Diabetes ... globe on a daily basis, but recent advancements in medical science may prove to ...
(Date:8/28/2015)... CA (PRWEB) , ... August 28, 2015 , ... ... to wound center management, Decatur County Memorial Hospital recently transitioned management companies to ... of Wound Center Management for their outpatient wound center. , Transitioning wound ...
(Date:8/28/2015)... ... August 28, 2015 , ... The Kentucky State Department of Workforce Investment Commissioner ... they are applying for, they are unable to pass the initial drug test and ... testing policies in order to be able to hire long-term, skilled talent. (1) Will ...
Breaking Medicine News(10 mins):Health News:The Patriot Project brings Chiropractic Care to the Armed Forces and their Families - Rapid Release Technology Joins the Effort to Recruit more Doctors to Pledge 2Health News:FCPX Effects Developer, Pixel Film Studios, Releases ProDrop Particles. 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 4Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 2Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 3Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 4
... are cancer survivors. On average, their medical care costs $4,000 ... have never had cancer, according to Penn State researchers. ... susceptible to later health complications and their total medical expenses ... from the moment they are diagnosed through the end of ...
... Sclerosis sufferers emotional support through group therapy sessions could ... almost 500 per patient, a study at The University ... a larger multi-centre study into the issue to establish ... services currently provided by the NHS. The study, ...
... predictors that can better identify patients who will benefit from ... small but real chance of cure in select patients with ... , a peer-reviewed journal of the American Cancer Society, the ... cancer patients. , Radiation is often used to treat ...
... study suggests that the brain activity of teens, recorded while ... popularity of the songs. "We have scientifically demonstrated that ... of people to predict cultural popularity," says Gregory Berns, a ... Journal of Consumer Psychology is publishing the results ...
... By Steven Reinberg HealthDay Reporter , FRIDAY, June ... phones might cause brain tumors continues, as a new international study ... users or who have used them for a long time. ... was not involved with the latest research, but said that "the ...
... SATURDAY, June 11 (HealthDay News) -- Baseline concussion tests for ... an expert warns. Baseline concussion testing provides a baseline ... working memory and attention span. Athletes who suffer a concussion ... in the score, they are typically banned from play until ...
Cached Medicine News:Health News:Cancer survivors spend more on health care 2Health News:Group therapy helps MS sufferers cope with depression, study finds 2Health News:Group therapy helps MS sufferers cope with depression, study finds 3Health News:Certain head and neck cancer patients benefit from second round of treatment 2Health News:Teen brain data may predict pop song success, Emory study finds 2Health News:Teen brain data may predict pop song success, Emory study finds 3Health News:Heavy Cell Phone Use Might Raise Risk of Brain Tumors 2Health News:Heavy Cell Phone Use Might Raise Risk of Brain Tumors 3Health News:Validity of Baseline Concussion Tests Questioned 2
... versatile automated strip washer which comes equipped with ... contained and programmable instrument. It allows for full ... dripping of a simple squeeze bottle to the ... 1 x 12 strips or a full 96-well ...
... High throughput washer for ... high throughput system washer ... more powerful dispensing line ... a stronger, external vacuum ...
High-quality microplate washer with robot compatibility. It offers additional washing capacity, first-rate efficiency in high-throughput and research applications....
The Wellwash 4 Mk 2 combines high performance and flexibility with reliability, simplicity and ease of use....
Medicine Products: